Navigation Links
ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Date:1/6/2009

PARIS, France, January 6 /PRNewswire-FirstCall/ --

- Early Renewal of the Agreement to Extend the Collaboration Until December 2011

- Expansion of the Scope of the Collaboration to Include Antibody Discovery in Ophthalmology

- Revised Commercial Terms and Payments to ExonHit if Allergan Sublicenses to a Third Party

ExonHit Therapeutics (Alternext: ALEHT) today announced a reinforcement of its existing drug discovery collaboration with Allergan Sales, LLC (NYSE: AGN). The collaboration is extended until December 2011, includes antibody discovery within the scope of the research activities and encompasses revised commercial terms.

The collaboration which has been renewed several times and initiated in December 2002 focuses on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology. EHT/AGN 0001, the most advanced compound out of the collaboration, is currently ending Phase I clinical trials for pain indications. EHT/AGN 0002 and other compounds are in pre-clinical testing for indications in pain, ophthalmology or neurodegenerative diseases.

Allergan exercised its option to extend this collaboration until December 2011 earlier than anticipated. As part of the renewal agreement, Allergan will provide ExonHit with increased quarterly research funding instead of a single payment.

The scope of the collaboration is expanded to include epitope* discovery for the development of antibody therapeutics in ocular disorders. ExonHit's unique gene profiling technology can readily be applied to identify disease specific target proteins, but also pinpoints novel epitopes present in those proteins, which are produced via alternative splicing. ExonHit's approach offers the potential be
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
9. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., , PISCATAWAY, N.J., Dec. 3 /PRNewswir...letin Board: MLSS), the recognized leader in advan...t had entered into a joint venture with China Nati...) and Yichang Humanwell Pharmaceutical Co. Ltd., b... (the "PRC"), to develop orthopedic and epidural d...
(Date:12/3/2009)..., , WALTHAM, Mass., Dec. 3 /PRNewswire...ing research and advisory firms focusing on pharma... type 2 diabetes drug market in Brazil will grow f...The projected 15 percent annual growth rate is att...pulation, increased use of new generation antidiab...
(Date:12/3/2009)..., , SAN DIEGO, Dec. 3 Amir...sitive data from a Phase 1 clinical study of AM461...f the DP2 (also known as CRTH2) receptor. ,, ...tional pharmacodynamic (PD) effect can be achieved...date demonstrates a good safety profile. AM461 is...
Breaking Medicine Technology:Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 1BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 2BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 3Record 73 4 Million Pounds Collected in Letter Carriers National Food Drive 47476 1Record 73 4 Million Pounds Collected in Letter Carriers National Food Drive 47476 2Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 1Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 2Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 3
...at Tufts Medical Center have created a formula for... certain genetic profiles and lifestyle behaviors ...tion (AMD), a potentially blinding condition that ...mericans and is increasing dramatically as the pop...eddon, MD, ScM, Professor of Ophthalmology at Tuf...
...44th Annual Meeting of EASL , , Management to Dis...nancial Results Call at 5 P.M. EDT Today , , SAN...sdaq: ANDS ) today announced that ANA598, the Co...inhibitor, demonstrated potent antiviral activity ...se Ib study in which patients chronically infected...
Other Medicine Technology:Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD) 2ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 2ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 3ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 4ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 5ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 6ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 7ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 8
(Date:12/4/2009)...nhibOx, a leading developer of novel and effective...ned forces with MolPort, an innovator in rare chem...hemical trading platform and builds database of co...s database and its updates to computational chemis...irtual screening procedures. Once they identify su...
(Date:12/4/2009)...st-Selling author and Personal & Organizationa...Transformation through Accountability! , ...4, 2009 -- IMPAQ Accountability Business Consult...est-selling Author, renowned Speaker, and CEO &...ants Inc., will present at the 14th International ...
(Date:12/3/2009)...iropractic Traffic has gotten into the holiday spi...rketing tool. $1 gets chiropractors 3 months of un... Traffic is even including chiropractic promotiona... (PRWEB) December 3, 2009 -- Chiropractic Marke...tool. Chiropractic Marketing expertise provided b...
(Date:12/3/2009)...., Dec. 3 The development of Unive...MCPP) reached a milestone today with a "topping ou... construction at the new hospital that will replac..., (Photo: http://www.newscom.com/cgi-bin/prnh/... a steelworkers, tradition in which a steel beam c...
(Date:12/3/2009)... The American Medical A...tates District Court for the Southern District of ...reviously disclosed $350 million settlement that w...Health Group. ,, The action brought by the AMA,...ouri State Medical Association, along with several...
Breaking Medicine News(10 mins):Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3Health News:Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference 2Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 3Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 4Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2
... 26 days across deserts and mountains, a group of ...oss-country motorbike// expedition to spread aware...ebruary 26 from Bangalore, Karnataka, the group of...in other such expeditions before but they have bee...
...ildhood could fall victims to other types of cance... Early attention and prompt treatment could help...es more likely to develop other types of cancers t...ute lymphoblastic leukemia as children and adolesc...
...ng center and cervical cancer screening program wi...rba Gandhi Hospital// (KGH) at Chennai, capital of... to determine the cause of abnormalities found in ...ican anatomist. It is used to detect changes that ...
...ave demanded a commitment for more funding if talk...nt review of the NHS Wheelchair// and Seating Serv...0m a year. But the Scottish Executive has agreed a... too lightly. Meanwhile BBC Scotland has come to u...
... been established at Kattankulathur, off Chennai, ...//. It will be functioning as part of the SRM Med.... Sathyanarayanan, Vice Chancellor, SRM University... It would commence from the academic year 20...
...tte smoking may actually aid in decreasing the ris...quential association// between smoking and reduced...s conducted by Evan L. Thacker and colleagues from...ibilities of neuro-protective chemicals that may b...
Other Medicine News:Health News:Cross-country Mobike Expedition to Spread AIDS Awareness 2Health News:New School of Public Health in Chennai 2
... A Test gives your laboratory clear-cut results in...icile, you can't afford to wait. For any laborator...t its suspected C. difficile samples for testing, ...ill cut costs and minimize your time-to-results wh...
Clearview C DIFF A
...ion, accuracy and easy operation TOMEYs patented l...viding high resolution. The laser alignment system... cone design eliminates nose & brow shadow & provi...l of the rings promotes patient comfort. New TMS S...
Pachycam
Medicine Products: